[Contribution of gadolinium DOTA in primary tumors of bone and soft tissue]
Related Experiment Video
Updated: Sep 30, 2026
Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers
Published on: July 17, 2012
D Vanel1, C Coffre, G Contesso
1Institut Gustave-Roussy, Villejuif.
Abstract:
20 patients with a primary musculo skeletal tumor were investigated by MRI to assess the efficacy of Gd DOTA. The essential contribution is that it distinguishes the active parts of the lesion, intratumoral necrosis or sequelae cavities that do not take up the contrast medium. The injection does not allow for differentiation between tumor recurrence and treatment-induced inflammatory abnormality.
Insights
Gadolinium-based contrast agent Gd-DOTA on MRI helps distinguish active tumor tissue from necrosis in musculoskeletal tumors. However, it cannot differentiate between tumor recurrence and treatment-induced inflammation.
Area of Science:
- Musculoskeletal Radiology
- Oncologic Imaging
- Magnetic Resonance Imaging
Background:
- Accurate assessment of musculoskeletal tumors is crucial for treatment planning.
- Distinguishing active tumor from post-treatment changes can be challenging.
- Gadolinium-based contrast agents are frequently used in MRI for tumor evaluation.
Purpose of the Study:
- To evaluate the efficacy of Gadolinium-DOTA (Gd-DOTA) enhanced MRI in characterizing primary musculoskeletal tumors.
- To determine if Gd-DOTA can differentiate active tumor components from necrotic areas or post-treatment cavities.
- To assess the utility of Gd-DOTA in distinguishing tumor recurrence from treatment-induced inflammatory abnormalities.
Main Methods:
- Magnetic Resonance Imaging (MRI) was performed on 20 patients with primary musculoskeletal tumors.
- Gd-DOTA was administered as an intravenous contrast agent.
- Image analysis focused on contrast enhancement patterns within the lesions.
Main Results:
- Gd-DOTA effectively highlighted active tumor areas.
- Necrotic regions and sequelae cavities within the tumors did not uptake the contrast medium, aiding in their identification.
- Gd-DOTA administration did not allow for differentiation between tumor recurrence and inflammatory changes post-treatment.
Conclusions:
- Gd-DOTA enhanced MRI is valuable for differentiating active tumor from necrosis in musculoskeletal lesions.
- The contrast agent's utility is limited in distinguishing tumor recurrence from treatment-induced inflammation.
- Further imaging techniques may be required for definitive differentiation in post-treatment settings.
